Schoenfield L J, Marks J W
Department of Medicine, Cedars-Sinai Medical Center, UCLA 90048.
Am J Surg. 1993 Apr;165(4):427-30. doi: 10.1016/s0002-9610(05)80934-1.
The appropriate selection of patients for treatment with oral ursodeoxycholic acid (UDCA)--a drug that has virtually no side effects--results in about 50% of patients experiencing safe dissolution of gallstones within 2 years. Eligible patients have small (less than 20 mm in diameter) radiolucent gallstones in a gallbladder visualized by oral cholecystography (OCG); ideal candidates are thin women who have gallstones that are less than 15 mm in diameter, floating when observed by OCG, or of low density on computed tomographic (CT) scanning. Contact dissolution with methyl tert-butyl ether (MTBE) is rapid, effective more often than UDCA, and safe but requires the expertise of an interventional radiologist. Any size and number of cholesterol gallstones that are not CT-dense will be dissolved by MTBE, leaving at most only insoluble debris that is clinically innocuous. Although gallstones recur after dissolution by UDCA or MTBE in 50% of patients within 5 years, recurrent gallstones are usually asymptomatic and/or can probably be dissolved. We conclude that oral or contact dissolution provides an alternative treatment to cholecystectomy for about 30% of patients with symptomatic gallstones.
对于口服熊去氧胆酸(UDCA)这种几乎没有副作用的药物,合适的患者选择可使约50%的患者在2年内胆结石安全溶解。符合条件的患者在口服胆囊造影(OCG)显示的胆囊中有小的(直径小于20毫米)透光性胆结石;理想的候选者是体型瘦的女性,其胆结石直径小于15毫米,在OCG观察时可漂浮,或在计算机断层扫描(CT)上呈低密度。用甲基叔丁基醚(MTBE)进行接触溶解速度快,比UDCA更有效,且安全,但需要介入放射科医生的专业技能。任何大小和数量的非CT致密性胆固醇胆结石都可被MTBE溶解,最多只留下临床上无害的不溶性碎片。虽然在5年内,50%的患者在UDCA或MTBE溶解胆结石后会复发,但复发性胆结石通常无症状和/或可能再次被溶解。我们得出结论,对于约30%有症状胆结石的患者,口服或接触溶解为胆囊切除术提供了一种替代治疗方法。